UK Markets closed

Evotec SE (EVO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
19.95-0.93 (-4.45%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close20.88
Open20.41
Bid18.81 x 1100
Ask26.80 x 800
Day's range19.95 - 20.43
52-week range17.07 - 26.57
Volume34,656
Avg. volume195,716
Market cap6.939B
Beta (5Y monthly)0.91
PE ratio (TTM)23.60
EPS (TTM)0.85
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.67
  • EQS Group

    Evotec and Lilly enter into drug discovery collaboration in metabolic diseases

    DGAP-News: Evotec SE / Key word(s): Miscellaneous18.01.2022 / 07:30 The issuer is solely responsible for the content of this announcement. COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA-DRIVEN DRUG DISCOVERY AND DEVELOPMENT PLATFORMS LILLY HAS THE RIGHT TO SELECT UP TO FIVE PROGRAMMES Hamburg, Germany, 18 January 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced

  • EQS Group

    Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach

    DGAP-News: Evotec SE / Key word(s): Miscellaneous11.01.2022 / 07:30 The issuer is solely responsible for the content of this announcement. EXPANSION LEVERAGES A PROPRIETARY EVOTEC PLATFORM IN THE FIELD OF TARGETED PROTEIN DEGRADATION TO TACKLE SELECTED TARGETS WITH RELEVANCE FOR A RANGE OF NEURODEGENERATIVE CONDITIONS EVOTEC RECEIVES PAYMENTS OF IN TOTAL US$ 15 M FROM BRISTOL MYERS SQUIBB Hamburg, Germany, 11 January 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;

  • EQS Group

    Evotec receives € 7.5 m grant for development of COVID-19 therapeutic

    DGAP-News: Evotec SE / Key word(s): Miscellaneous03.01.2022 / 07:30 The issuer is solely responsible for the content of this announcement. EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19 EVOTEC IS DEVELOPING A HIGHLY POTENT IMMUNOMODULATORY MOLECULE THAT HOLDS THE POTENTIAL TO AMPLIFY THE IMMUNE RESPONSE AND REDUCE THE RISK OF DIFFICULT DISEASE PROGRESSION AND HOSPITALISATIONHamburg, Germany